Hyperglycemia and Risk of All-cause Mortality Among People Living With HIV With and Without Tuberculosis Disease in Myanmar (2011–2017)

Nang Thu Thu Kyaw,1,8* Srinath Satyanarayana,2 Htun Nyunt Oo,3 Ajay M. V. Kumar,4 Anthony D. Harries,4,5 Si Thu Aung,6 Khine Wut Yee Kyaw,1 Khang Hnin Phyoe,1 Thet Ko Aung,1 and Matthew J. Magee3

1Center for Operational Research, International Union Against Tuberculosis and Lung Disease, The Union Myanmar Office, Mandalay, Myanmar; 2Center for Operational Research, International Union Against Tuberculosis and Lung Disease, The Union South-East Asia Office, New Delhi, India; 3National HIV/AIDS Program, Department of Public Health, Nay Pyi Taw, Myanmar; 4Center for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France; 5London School of Hygiene and Tropical Medicine, London, UK; 6National Tuberculosis Program, Department of Public Health, Nay Pyi Taw, Myanmar; 7Integrated HIV Care Program, International Union Against Tuberculosis and Lung Disease, The Union Myanmar Office, Mandalay, Myanmar; 8Division of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia

Background. There is limited empirical evidence on the relationship between hyperglycemia, tuberculosis (TB) comorbidity, and mortality in the context of HIV. We assessed whether hyperglycemia at enrollment in HIV care was associated with increased risk of all-cause mortality and whether this relationship was different among patients with and without TB disease.

Methods. We conducted a retrospective analysis of adult (≥15 years) HIV-positive patients enrolled into HIV care between 2011 and 2016 who had random blood glucose (RBG) measurements at enrollment. We used hazards regression to estimate associations between RBG and rate of all-cause mortality.

Results. Of 25,851 patients, 43% were female, and the median age was 36 years. At registration, the median CD4 count (interquartile range [IQR]) was 162 (68–310) cell/mm³, the median RBG level (IQR) was 88 (75–106) mg/dL, and 6.2% (95% confidence interval [CI], 6.0%–6.5%) had hyperglycemia (RBG ≥140 mg/dL). Overall 29% of patients had TB disease, and 15% died during the study period. The adjusted hazard of death among patients with hyperglycemia was significantly higher (adjusted hazard ratio [aHR], 1.2; 95% CI, 1.1–1.4) than among those with normoglycemia without TB disease, but not among patients with TB disease (aHR, 1.0; 95% CI, 0.8–1.2). Using 4 categories of RBG and restricted cubic spline regression, aHRs for death were significantly increased in patients with RBG of 110–140 mg/dL (categorical model: aHR, 1.3; 95% CI, 1.2–1.4; restricted spline: aHR, 1.1; 95% CI, 1.0–1.1) compared with those with RBG <110 mg/dL.

Conclusions. Our findings highlight an urgent need to evaluate hyperglycemia screening and diagnostic algorithms and to ultimately establish glycemic targets for PLHIV with and without TB disease.

Keywords. diabetes mellitus; loss to follow-up; noncommunicable disease; restricted cubic spline; sensitivity analysis.

Hyperglycemia during infectious disease is a predictor of increased morbidity and mortality. Previous studies have reported that hyperglycemia with or without diabetes mellitus (DM) is associated with poor outcomes in sepsis, dengue, pneumonia, and tuberculosis (TB) [1–4]. However, whether hyperglycemia in people living with HIV infection (PLHIV) is associated with higher mortality or morbidity is not clear.

There are biological mechanisms by which hyperglycemia likely increases the risk of mortality in hospitalized critical care patients [1, 5]. However, in patients with HIV/TB, the extent to which hyperglycemia impacts mortality risk is poorly understood. Both type 1 and 2 DM immunopathy increase the risk of TB [6–9], and hyperglycemia or poor glycemic control is associated with adverse TB treatment outcomes [10–12]. In addition, TB enhances HIV disease progression via the inflammatory response to TB disease, and globally TB remains one of the most important causes of mortality among PLHIV [13–15]. Concomitantly, HIV may increase the risk of DM due to chronic inflammation, adverse effects of antiretroviral therapy, and accelerated epigenetic aging among PLHIV [16–20]. Early evidence indicates that DM is also associated with an increased risk of mortality in PLHIV [21], but whether hyperglycemia increases the risk of mortality in PLHIV due to its effect on TB or whether there is a direct association is unknown.

There is a lack of empirical evidence regarding the relationship between hyperglycemia, TB comorbidity, and all-cause mortality in the context of HIV to guide the clinical management of dysglycemia and TB in PLHIV [22]. Therefore, in this
observational study, we assessed whether hyperglycemia at the
time of enrollment to HIV care was associated with increased
risk of all-cause mortality in PLHIV during 5 years of follow-up.
We also examined whether the hyperglycemia and mortality
relationship was different among patients with and without TB
disease.

METHODS

Design and Setting

We conducted a retrospective cohort study using routinely col-
lected data from PLHIV registered in the Integrated HIV Care
Program in Myanmar between January 2011 and December
2016 among those who had random blood glucose (RBG) mea-
sured at enrollment to HIV care.

Standard of care at 33 HIV clinics throughout Myanmar
included clinical and laboratory evaluation, including blood
glucose measurement and TB disease screening at enrollment,
TB disease screening during quarterly follow-up visits, treat-
ment and prophylaxis for opportunistic infections, and pro-
viding antiretroviral therapy (ART) according to World Health
Organization (WHO) and national HIV treatment guidelines.
Patients with abnormal RBG levels were referred to diabetes
clinics for diagnosis and management. Although cut-points
for abnormal RBG were not indicated in clinical guidelines,
patients with an RBG level >110 mg/dL were typically evaluated
during diabetes diagnosis and management.

Study Participants

Eligible patients included adult (≥15 years) PLHIV who were
registered at HIV clinics between January 2011 and December
2016 and were screened for TB disease and received a random
blood glucose test at the time of registration to the HIV clinic.
Patients were followed up from the time of registration until
June 30, 2017. Patients who received isoniazid preventive ther-
apy and second-line anti-TB treatment for drug-resistant TB
were excluded.

Data Source and Management

Patients’ data were recorded using standardized forms at each
clinic visit by medical officers and entered into an electronic
database by data entry operators. Data for this retrospective study
were extracted from the electronic database in December 2017.

Measures and Definitions

The primary exposure of interest was RBG measurement at
enrollment into HIV care. We used RBG levels as continuous
and categorical variables. We categorized RBG dichotomously;
≥140 mg/dL was defined as hyperglycemia according to pre-
vious studies and WHO 2-hour postprandial blood glucose
classification for diagnosis of prediabetes [23–25]. Additionally,
RBG was defined with a 4-level categorical variable: <110 mg/ 
dL, 110–140 mg/dL, 141–199 mg/dL, and >199 mg/dL.

The study’s primary outcome was all-cause mortality, which
was determined using patients’ medical records. Patients’ death
status was reported by family members, caretakers, or peer vol-
unteers when the patient died at home or in the hospital. Date of
death was recorded from hospital records if patients died at the
hospital or as reported by families if the patient died at home.
Patients’ TB disease status was a key covariate determined by
firstline anti-TB treatment use for any duration for either pul-
omonal or extrapulmonary TB disease. TB disease status was
categorized as prevalent (at the time or within 1 month of clinic
registration), incident (any time during follow-up but >1 month
after registration), and any TB disease (either prevalent or inci-
dent). Firstline anti-TB treatment in this setting included isoni-
azid, rifampicin, pyrazinamide, ethambutol, and streptomycin.

Additional key covariates included age, gender, body
mass index (BMI), CD4 cell count, WHO clinical disease
staging [26], anemia, hepatitis B surface antigen, and hepa-
titis C antibody at the time of registration to HIV care. BMI
and anemia were defined by WHO guidelines for Asian popu-
lations [27, 28].

Data Analyses

We used logistic regression to assess unadjusted associations
between patients’ clinical characteristics and hyperglycemia.
We calculated incidence rate (IR) per 100 person-years (PYs) by
dividing the number of deaths by the person-time in years and
95% confidence intervals (CI) using the quadratic approxima-
tion to the Poisson log likelihood for the log-rate parameter. We
used cumulative incidence curves to estimate the unadjusted
association between RBG and time to all-cause mortality and
Cox proportional models to estimate hazard ratios (HRs) and
95% CIs to compare hyperglycemia at registration and hazard
of mortality among all PLHIV. Survival time was defined as
the number of days between the date of registration and date
of death or censorship. Patients were right-censored if they
were lost to follow-up, transferred to other health care facilities,
or alive at the end of the study (June 30, 2017). Proportional
assumptions were assessed using the log-log survival curves,
and goodness of fit was assessed using Schoenfeld residuals
[29]. We used a priori criteria to identify potential confounding
covariates based on directed acyclic graph theory and observed
bivariate associations [30]. Statistical interaction between TB
disease and RBG with mortality was assessed using likelihood
ratio tests, and HRs were stratified by TB disease status. We
also tested whether the relationship between RBG and mortal-
ity was linear. We then estimated HRs with nonlinear catego-
ries of RBG, including (1) estimation of adjusted hazard ratios
(aHRs) with 4 categories of RBG (<110, 110–140, 141–199,
>199 mg/dL) and (2) restricted cubic spline regression using
4 equal knots and 3 reference points of RBG at 110, 140, 199,
and 260 mg/dL [31, 32]. We performed sensitivity analyses to
assess potential systematic error due to competing risks using
cumulative incidence functions and subdistribution hazard functions according to Fine and Gray [33] and to quantify systematic error due to loss to follow-up and nonindependence of censoring [34]. A 2-sided $P$ value <.05 was considered statistically significant in all analyses. Analyses were performed using STATA, version 14.0 (StataCorp, College Station, TX).

**Ethical Approval**

Ethical approval was obtained from the Ethical Review Committee, Department of Medical Research, Myanmar, and the Ethics Advisory Group, International Union Against Tuberculosis and Lung Disease, Paris, France.

**RESULTS**

**Patient Factors Associated With Hyperglycemia**

During the study, 25,851 patients (Figure 1) provided 64,755 person-years of follow-up time. The median age of study participants (interquartile range [IQR]) was 36 (30–42) years, 43% were female, and the median CD4 count at registration (IQR) was 162 (68–310) cell/mm$^3$. At registration, the median RBG (IQR) was 88 (75–106) mg/dL, and 6.2% (95% CI, 6.0%–6.5%) had hyperglycemia. Overall, 91% ($n = 23,490$) of patients received ART, 29% ($n = 7,495$) of patients had TB disease, and 15% ($n = 3,985$) died during the study period. Patients aged 25–45 years (odds ratio [OR], 1.7; 95% CI, 1.3–2.2) or ≥46 years old (OR, 3.1; 95% CI, 2.4–4.0), male patients (OR, 1.3; 95% CI, 1.2–1.4), patients who were overweight (OR, 1.4; 95% CI, 1.2–1.6) or obese (OR, 1.4; 95% CI, 1.1–1.7), and those who had hepatitis C co-infection (OR, 1.5; 95% CI, 1.3–1.8) were associated with hyperglycemia at the time of registration (Table 1).

**Overall Risk of All-cause Mortality**

Among all PLHIV, the IR of all-cause mortality was 6 deaths per 100 person-years (Table 2), and the median time to death from enrollment among patients who died (IQR) was 140 (63–387) days. The IR of all-cause mortality among patients with hyperglycemia was significantly higher than among patients with normoglycemia (IR, 7.3; 95% CI, 6.5–8.2; vs IR, 6.1; 95% CI, 5.9–6.3 per 100 person-years; $P < .05$). The unadjusted hazard of death among patients with hyperglycemia was 1.1 (95% CI, 1.0–1.3) times the hazard of normoglycemic patients (Table 2 and Figure 2A). Other patient factors associated with increased hazard of death included having TB disease (HR, 1.4; 95% CI, 1.3–1.5), being underweight (HR, 2.1; 95% CI, 1.9–2.3), having a lower CD4 count (patients with CD4 count 200–350: HR, 1.6; 95% CI, 1.4–1.9; patients with CD4 <200: HR, 4.2; 95% CI, 3.7–4.7), not being on ART (HR, 5.3; 95% CI, 4.9–5.8), being anemic (patients with mild to moderate anemia: HR, 2.8; 95% CI, 2.5–3.1; patients with severe anemia: HR, 6.4; 95% CI, 5.8–7.2), and having hepatitis B co-infection (HR, 1.2; 95% CI, 1.1–1.4).

**Hyperglycemia and Mortality Among HIV-Positive Patients With and Without TB Disease**

After adjusting for age, gender, BMI, and hepatitis C co-infection, the hazard of all-cause mortality was higher among hyperglycemic patients compared with patients with normoglycemia (aHR, 1.1; 95% CI, 1.0–1.3) (Table 3). A significant interaction between hyperglycemia and TB disease was observed ($P < .001$). Among patients without TB disease, the IR of all-cause mortality among patients with normoglycemia was 5.5 per 100 PYs (95% CI, 5.3–5.7), and among hyperglycemic patients, it was 7.3 per 100 PYs (95% CI, 6.3–8.5) (Figure 2A).

---

**Figure 1.** Flow diagram of patients included in the study stratified by their comorbidity with tuberculosis (TB) status and outcomes among people living with HIV registered in HIV clinics in Myanmar between 2011 and 2016. *Patients with TB disease include both prevalent TB at the time of registration to the program and incident TB developed during follow-up. ‡Transferred out to other programs to continue care. Abbreviations: IPT, isoniazid preventive therapy; RBG, random blood glucose.
Similarly, the cumulative incidence of all-cause mortality was higher, and the adjusted hazard of death was significantly higher (aHR, 1.2; 95% CI, 1.0–1.4) among patients with hyperglycemia compared with patients with normoglycemia (Table 3).

Among patients with TB disease, the IR of all-cause mortality was 7.4 per 100 PYs (95% CI, 7.0–7.8) among normoglycemic patients and was 7.3 per 100 PYs (95% CI, 5.9–8.8) among those with hyperglycemia (Figure 2C). In patients with TB disease, the adjusted hazard of mortality was similar in those with and without hyperglycemia (aHR, 1.0; 95% CI, 0.8–1.2). The adjusted hazard of mortality was not significantly different by hyperglycemia status when TB disease was categorized separately as prevalent TB (aHR, 1.0; 95% CI, 0.8–1.2) and incident TB (aHR, 1.2; 95% CI, 0.6–2.3) (Table 3).

### Categorical and Restricted Cubic Spline Models

We found that the adjusted HRs of mortality across different glycemic levels were nonlinear ($P < .0001$). Using 4 categories of RBG, the adjusted hazard for all-cause mortality was increased in the group of patients with glycemic levels between 110 and 140 mg/dL compared with those with RBG <110 mg/dL (HR, 1.2; 95% CI, 1.0–1.4). Among patients without TB disease, those with RBG 110–140 mg/dL and RBG 141–199 mg/dL had a significantly increased hazard of death (aHR, 1.3; 95% CI, 1.2–1.4; aHR, 1.2; 95% CI, 1.1–1.5) (Table 3). In restricted cubic spline regression, the aHRs were significantly increased among patients with a glycemic level between 110 and 140 mg/dL but not among patients with an RBG of 141–190 mg/dL or >199 mg/dL (aHR, 1.1; 95% CI, 1.0–1.1; vs aHR, 1.1; 95% CI, 0.9–1.2; or aHR, 1.1; 95% CI, 0.8–1.3) (Table 3; Supplementary Figure 1).

### Table 1. Demographic and Clinical Characteristics of Patients Stratified by Hyperglycemia and Factors Associated With Hyperglycemia Among PLHIV (≥15 Years) Registered in HIV Clinics in Myanmar Between January 2011 and December 2016

| Total | Normoglycemia ≤140 mg/dL | Hyperglycemia >140 mg/dL | OR  | 95% CI |
|-------|--------------------------|---------------------------|-----|-------|
| No.   | No. %                    | No. %                     |     |       |
| Total | 25 851 24 237 93.8       | 1614 6.2                  |     |       |
| Age at enrollment, y | 15–24                     | 1889 1823 96.5             | 66 3.5 | Ref  |
|       | 25–45                     | 19 878 18 740 94.3         | 1138 5.7 | 1.7 (1.3 to 2.2) |
|       | ≥46                       | 4084 36 74 90.0            | 410 10.0 | 3.1 (2.4 to 4.0) |
| Gender | Female                    | 11 054 10 460 94.6         | 594 5.4 | Ref  |
|       | Male                      | 14 797 13 777 93.1         | 1020 6.9 | 1.3 (1.2 to 1.4) |
| BMI at enrollment, kg/m² | Underweight (<18.5)       | 8079 7599 94.1             | 480 5.9 | 1.1 (1.0 to 1.2) |
|       | Normal (18.5–22.9)        | 8508 80 43 94.5            | 465 5.5 | Ref  |
|       | Overweight (23–275)       | 3041 2817 92.6             | 224 7.4 | 1.4 (1.2 to 1.6) |
| WHO staging at enrollment | 1 and 2                   | 11 179 10 510 94.0         | 669 6.0 | Ref  |
|       | 3 and 4                   | 14 590 13 650 93.6         | 940 6.4 | 1.1 (1.0 to 1.2) |
| ART at enrollment | On ART                    | 4 456 93.8                 | 30 6.2 | Ref  |
|       | Not on ART                | 25 365 23 781 93.8         | 1584 6.2 | 1.0 (0.7 to 1.5) |
| Anemia at enrollment | No anemia                 | 8896 75 81 93.6            | 515 6.4 | Ref  |
|       | Mild to moderate          | 15 105 14 192 94.0         | 913 6.0 | 1.0 (0.8 to 1.1) |
|       | Severe                    | 2221 20 56 92.6            | 165 7.4 | 1.2 (1.0 to 1.4) |
| Hepatitis B co-infection at enrollment | Negative                | 21 036 19 694 93.6         | 1342 6.4 | Ref  |
|       | Positive                  | 2049 1900 92.7             | 149 7.3 | 1.2 (1.0 to 1.4) |
| Hepatitis C co-infection at enrollment | Negative                | 2766 26 43 95.6            | 123 4.4 | 0.7 (0.5 to 0.8) |
|       | Unknown                   | 20 631 19 363 93.9         | 1268 6.1 | Ref  |
| TB disease comorbidity | Without TB disease        | 18 356 17 283 94.2         | 1073 5.6 | Ref  |
|       | With TB disease           | 7495 6954 92.8             | 541 7.2 | 1.3 (1.1 to 1.4) |

Bolded text indicates a $P$ value <.05. Some lower limits of CIs were >1 or <1, but due to the rounding to 2 decimal places, they became 1.00.

Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; OR, odds ratio; PLHIV, people living with HIV; TB, tuberculosis; WHO, World Health Organization.
Sensitivity Analyses
In competing risk analyses, both the cause-specific analysis (aHR, 1.2; 95% CI, 1.1–1.4) and subdistribution analysis (aHR, 1.2; 95% CI, 1.0–1.4) indicated an increased hazard of mortality due to hyperglycemia among patients without TB disease, but the association was not significant in the subdistribution analysis. Among patients with TB disease, the association between RBG and mortality was not significant in both models (cause-specific aHR, 1.0; 95% CI, 0.8–1.2; subdistribution aHR, 1.0; 95% CI, 0.9–1.2) (Supplementary Table 1).

During the study, there were 3506 (13.6%) patients lost to follow-up; of these, 2639 (75.3%) had a normoglycemic level and 867 (24.7%) had hyperglycemia. In sensitivity analyses that randomly assigned a death outcome to records that were lost to follow-up, the aHRs among all patients ranged from 0.6 to 2.7; among patients without TB disease, the aHR ranged from 0.6 to 2.6, and among patients with TB disease, the aHR ranged from 0.6 to 1.5 (Supplementary Table 2).

DISCUSSION
This large observational cohort of PLHIV from Myanmar found an important effect of hyperglycemia on all-cause mortality during 5 years of follow-up. More than 6% of PLHIV had hyperglycemia at the time of registration into HIV care, and 1 out of every 6 patients with hyperglycemia died during follow-up. Importantly, we also demonstrated that the relationship between hyperglycemia and all-cause mortality is different by...
TB disease status and the risk of mortality is nonlinear across glycemic levels. In analyses stratified by TB disease status, we reported that the rate of mortality in PLHIV with hyperglycemia but no TB disease (7 deaths per 100 PYs) was similar to the rate of mortality in patients with TB regardless of hyperglycemia status.

Figure 2. Nelson-Aalen plots of cumulative mortality stratified by hyperglycemia status (A) among all people living with HIV (PLHIV), (B) among PLHIV with tuberculosis (TB) disease, and (C) among PLHIV without TB disease enrolled in the Integrated HIV Care program in Myanmar between 2011 and 2017. Abbreviation: CI, confidence interval.
In this study, hyperglycemia among PLHIV increased the hazard of mortality by 10% compared with patients with normoglycemia levels, even after adjustment of confounding demographic and clinical factors. The highest hazard of mortality was observed with RBG of 110–140 mg/dL, whereas the hazard was similar comparing those with RBG >199 mg/dL with patients with <110 mg/dL. We hypothesized that previous DM diagnosis and treatment may modulate the association between glycemic status and mortality [35]; therefore, the observed U-shaped relationship may be due to preexisting DM diagnosis among patients with higher glucose levels (RBG, 141–199 mg/dL or >199 mg/dL). It is also plausible that patients with moderate hyperglycemia (RBG, 110–140 mg/dL) had stress hyperglycemia, resulting in more adverse outcomes compared with those with DM hyperglycemia.

Although few previous studies on DM and mortality in patients with HIV exist, limited evidence suggests that there is increased mortality due to comorbidity between hyperglycemia and HIV. For example, a cohort study of HIV-positive patients from Brazil during 1999–2011 reported that DM was a significant risk factor for mortality [21]. In another Brazilian study, a significantly higher proportion of annual deaths were due to DM in HIV/AIDS patients compared with a non-HIV control group (4.1% vs 3.9%) [36]. Similarly, a Swiss HIV cohort study (n = 8444) reported that among PLHIV, the 3-year hazard of death among DM was 3.75 (95% CI, 1.80–7.85) times the hazard of death among patients without DM [37].

Among HIV/TB patients, the incidence rate of mortality was similar in those with and without hyperglycemia at enrollment in HIV care in this cohort. However, our results contradict those from a cohort study conducted by Moreira et al. in Brazil, which...
reported that hyperglycemia was a risk factor for increased 1-year mortality among HIV/TB-co-infected patients (aHR, 3.72; 95% CI, 2.17–6.38) [38]. Our divergent findings may be due to different baseline characteristics of study patients and definitions of hyperglycemia. For example, the proportion of patients on ART in the Brazilian study was about 50%, whereas the ART coverage in our study was >90%. The protective effect of ART in our study might shift the hazard due to hyperglycemia on mortality in HIV/TB patients toward the null. Second, the study by Moreira et al. defined hyperglycemia using fasting blood glucose levels ≥126 mg/dL or glycated hemoglobin >6.5% (compared with our RBG of >140 mg/dL) and used multiple glucose measurements at different time points during anti-TB treatment. Patients with known DM were also excluded from the study by Moreira et al., whereas our study did not exclude patients with DM.

There are important clinical implications from this study. First, RBG levels >110 mg/dL may predict mortality among PLHIV. Because RBG is inexpensive and often standard of care, it could be readily used among PLHIV to augment risk profiles. However, where feasible, PLHIV with RBG >110 mg/dL should also be screened for DM using more accurate glycemic diagnostic tests at registration and during follow-up, and those diagnosed with DM should be referred for further treatment and management. Second, our study demonstrates the need for additional basic science and operational research to understand the immunopathology of how hyperglycemia may increase the risk of mortality among PLHIV and why there are differences between those with and without TB. Third, our results highlight the urgent need for clinical guidelines for blood glucose targets at registration and during follow-up, and those diagnosed with DM should be referred for further treatment and management. Second, our study demonstrates the need for additional basic science and operational research to understand the immunopathology of how hyperglycemia may increase the risk of mortality among PLHIV and why there are differences between those with and without TB. Third, our results highlight the urgent need for clinical guidelines for blood glucose targets among PLHIV and suggest that these targets may be different based on baseline glucose levels and comorbidity with TB disease.

Our study has limitations. First, there was potential misclassification of hyperglycemia status, as we relied on the only standard of care measure of dysglycemia (RBG) at HIV clinics in Myanmar. Compared with hemoglobin A1c or oral glucose tolerance tests, RBG is a less definitive measure for dysglycemia, and there is no consensus for classification of hyperglycemia by RBG alone. Nonetheless, we used different cut-points of RBG to define hyperglycemia and consistently found that hyperglycemia increased the risk of mortality among PLHIV, especially those without TB disease. Second, misclassification of the outcome (mortality) could not be ruled out, as 14% of patients were lost from care during follow-up. However, we performed sensitivity analyses using different plausible proportions of mortality among patients lost to follow-up [32, 33].

We demonstrated that even with high proportions of death among patients lost during follow-up, the estimated effect of hyperglycemia on mortality did not significantly change. Third, our study measured RBG at 1 time point. Hence, we could not determine changes in glucose levels during HIV care. Similarly, we did not have information on DM diagnosis or DM treatment, and therefore we could not determine whether the effect of glycemic level on hazard of mortality differed by DM status. Fourth, unmeasured confounders such as patients’ economic status, access to other health care, and presence of other chronic conditions such as hypertension and hyperlipidemia were not assessed. Therefore, we could not exclude the possibility of systematic error in our estimates due to residual confounding. Fifth, we excluded patients who did not have RBG at enrollment and patients who received isoniazid therapy from this study. Although these exclusions may have impacted the generalizability of our study results, the excluded patients’ demographic characteristics did not differ significantly from those included in the study (data not shown).

Despite limitations, there are important strengths to this study. We studied a large cohort of PLHIV with more than 65,000 person-years of follow-up time. We used various methods to estimate the effect of hyperglycemia on mortality among PLHIV, including methods that accounted for competing risks and loss to follow-up. Our multiple model specifications, thorough evaluation of RBG categories, and sensitivity analyses extend additional credibility to the validity of our results.

**CONCLUSIONS**

We found that hyperglycemia was associated with increased risk of all-cause mortality among PLHIV. Pertinent to clinical care, we observed that the effect of hyperglycemia was different by TB disease status; much of the increased mortality risk due to hyperglycemia was among PLHIV without TB disease. Important gaps in knowledge remain regarding how to systematically screen and diagnose hyperglycemia among PLHIV. Further research is urgently needed to establish glycemic targets among PLHIV. When and how to achieve glycemic targets will likely be different among patients with and without TB disease.

**Supplementary Data**

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Acknowledgments**

The authors are grateful to the clinical and administrative staff working with the National HIV/AIDS Program and The Union Mandalay office for their dedication in caring for patients and their attentiveness in accurately recording the patients’ data. All patients included in this study are also gratefully acknowledged.

**Financial support.** This work was supported by the Department for International Development (DFD; UK), which funded the Global Operational Research Fellowship Program at the International Union Against Tuberculosis and Lung Disease (The Union; Paris, France), where the first author works as an operational research fellow.
References

1. Leonidou L, Mouzaki A, Michalaki M, et al. Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. J Infect 2007; 55:340–6.
2. Htun NS, Odermatt P, Eze IC, et al. Is diabetes a risk factor for a severe clinical presentation of dengue?–review and meta-analysis. PLoS Negl Trop Dis 2015; 9:e0003741.
3. Chang JT, Dou HY, Yen CL, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc 2011; 110:372–81.
4. Podell BK, Ackart DE, Kirk NM, et al. Non-diabetic hyperglycemia exacerbates disease severity in Mycobacterium tuberculosis infected guinea pigs. PLoS One 2012; 7:e40824.
5. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009; 373:1798–1807.
6. Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association between diabetes mellitus and active tuberculosis: a systematic review and meta-analysis. PLoS One 2017; 12:e0187967.
7. Zheng C, Hu M, Gao F. Diabetes and pulmonary tuberculosis: a global overview with special focus on the situation in Asian countries with high TB-DM burden. Glob Health Action 2017; 10:1–11.
8. Martínez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol 2011; 41:617–26.
9. Kornfeld H, West K, Kane K, et al. High prevalence and heterogeneity of diabetics in patients with TB in South India: a report from the Effects of Diabetes On Tuberculosis Severity (EDOTS) study. Chest 2016; 149:1501–8.
10. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011; 9:81.
11. Magee MJ, Foote M, Maggio DM, et al. Diabetes mellitus and risk of all-cause mortality among tuberculosis patients in the state of Georgia, 2009–2012. Ann Epidemiol 2014; 24:369–375.
12. Lee P-H, Hu H, Lai T-C, Chiang C-Y, Chan C-C, Lin H-H. Glycemic control and diabetes mellitus and active tuberculosis: a cohort study. PLoS Med 2016; 13:e1002072.
13. Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat Rev Microbiol 2018; 16:80–90.
14. Mchunu G, van Griensven J, Hinderaker SG, et al. High mortality in tuberculosis patients despite HIV interventions in Swaziland. Public Health Action 2016; 6:105–10.
15. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic—when will we act? Lancet 2010; 375:1906–19.
16. Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep 2014; 11:271–8.
17. Prioreschi A, Mumbali BJ, Soepnel L, et al. Incidence and prevalence of type 2 diabetes mellitus with HIV infection in Africa: a systematic review and meta-analysis. BMJ Open 2017; 7:e013953.
18. Nasi M, De Biasi S, Gellibelli L, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol 2017; 187:44–52.
19. Nelson KN, Hui Q, Rimland D, et al. Identification of HIV infection-related DNA methylation sites and advanced epigenetic aging in HIV-positive, treatment-naive U.S. veterans. AIDS 2017; 31:571–5.
20. Ali MK, Magee MJ, Dave JA, et al. HIV and metabolic, body, and bone disorders: what we know from low- and middle-income countries. J Acquir Immune Defic Syndr 2014; 67:S27–39.
21. Moreira RC, Pacheco AG, Paula A, et al. Diabetes mellitus is associated with increased death rates among HIV-infected patients in Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses 2016; 32:1210–8.
22. Critchley JA, Restrepo BI, Ronacher K, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: part 1: epidemiology and clinical management. Chest 2017; 152:165–73.
23. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. 2006. http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/. Accessed June 27, 2018.
24. MacIntyre EJ, Majumdar SR, Gamble J-M, Minhas-Sandhu JK, Marrie TJ, Eurich DT. Stress hyperglycaemia and newly diagnosed diabetes in 2124 patients hospitalized with pneumonia. Am J Med 2012; 125:1036.e17–23.
25. Oswald GA, Smith CC, Betteridge DJ, Yudkin JS. Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J 1986; 293:917–22.
26. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015. http://www.who.int/hiv/pub/ guidelines/earlyrelease-avrisen/. Accessed October 22, 2015.
27. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363:157–63.
28. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. http://www.who.int/vmns/indicators/haemoglobin/en/. Accessed May 31, 2018.
29. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. 2nd ed. New York: Springer Science and Bussiness Media, LLC; 2005.
30. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999; 10:37–48.
31. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6:356–65.
32. May S, Bigelow C. Modeling nonlinear dose-response relationships in epidemiologic studies: statistical approaches and practical challenges. Dose Response 2006; 3:474–90.
33. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496–509.
34. Greenland S. Basic methods for sensitivity analysis of biases. Int J Epidemiol 1996; 25:1107–16.
35. Kriemslay JS, Egli M, Kiss A, et al. Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study. Crit Care 2013; 17:837.
36. Paula AA, Schechter M, Tuboi SH, et al. Continuous Increase of Cardiovascular Diseases, Diabetes, and Non-HIV Related Cancers as Causes of Death in HIV-Infected Individuals in Brazil: An Analysis of Nationwide Data. PLOS ONE 2014; 9:e94636.
37. Hase B, Ledergerber B, Furrer H, et al. Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV Cohort Study: Clin Infect Dis 2011; 53:1130–9.
38. Moreira J, Castro R, Lamas C, et al. Hyperglycemia during tuberculosis treatment increases morbidity and mortality in a contemporary cohort of HIV-infected patients in Rio de Janeiro, Brazil. Int J Infect Dis 2018; 69:11–9.